BiotechTube
All Reports
🫁

Respiratory

Competitive landscape report · 53 products · 21 companies

Executive Summary

The respiratory landscape features 53 products in active development across 21 companies. The space remains highly competitive with significant activity across all clinical stages.

12 products are currently in Phase 3 trials, 22 in Phase 2, and 7 in Phase 1. Leading companies by pipeline count include Eli Lilly, Rein Therapeutics, Cereno Scientific.

2 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
DuleraAsthma
Merck
Approved
85
2
Zopapogene imadenovec (Zopa)Recurrent Respiratory Papillomatosis
Precigen
Approved
80
3
RoflumilastAsthma
AstraZeneca
Phase 3
77
4
tadalafil + tadalafilHypertension, Pulmonary
Eli Lilly
Phase 3
77
5
Pemetrexed + CarboplatinNon Small Cell Lung Carcinoma
Eli Lilly
Phase 3
77
6
Pemetrexed + Cisplatin + Placebo + PemetrexedNon-Small Cell Lung Cancer
Eli Lilly
Phase 3
77
7
pemetrexed + docetaxelNon-Small Cell Lung Cancer
Eli Lilly
Phase 3
77
8
PemCarbo + Pem onlyNon-small Cell Lung Cancer
Eli Lilly
Phase 3
77
9
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibMetastatic Non-Small Cell Lung Cancer
Eli Lilly
Phase 3
77
10
CT-P51 + EU-approved KeytrudaNon Squamous Non Small Cell Lung Cancer
Celltrion
Phase 3
77

Top Companies by Pipeline Count

1Eli Lilly26 products2Rein Therapeutics3 products3Cereno Scientific2 products4Precigen2 products5MAIA Biotechnology2 products6BioAtla2 products7Celltrion2 products8AstraZeneca1 products9Merck1 products10Avalyn Pharmaceuticals1 products

Phase Distribution

Pre-clinical
4
Phase 1
7
Phase 1/2
6
Phase 2
22
Phase 3
12
Approved
2

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports